<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7310596\results\search\drug\results.xml">
  <result pre="al. and Li et al. have described increased levels of" exact="creatine" post="kinaseâ€&quot;myocardial band (CK-MB), myoglobin, and NT-pro-BNP in COVID patients,"/>
  <result pre="and the potential for pro-arrhythmia. Although data on outcomes with" exact="hydroxychloroquine" post="are not available, it is widely used in hospitals"/>
  <result pre="Society released recently in collaboration with the ACC and AHA," exact="hydroxychloroquine" post="use must be closely monitored in certain patient groups."/>
  <result pre="the known strategies to counter them. Among the treatments employed," exact="chloroquine" post="and hydroxychloroquine, antiretrovirals (lopinavir and ritonavir), ribavarin, remdesivir, corticosteroids,"/>
  <result pre="inhibitors), and immunoglobulin therapy (convalescent plasma) have been prominent [92]." exact="Chloroquine" post="and hydroxychloroquine have been used to treat patients with"/>
  <result pre="immunoglobulin therapy (convalescent plasma) have been prominent [92]. Chloroquine and" exact="hydroxychloroquine" post="have been used to treat patients with COVID-19 in"/>
  <result pre="is useful to monitor [65]. A detailed treatment workflow with" exact="hydroxychloroquine" post="is provided in Fig.Â 3. Lopinavir and ritonavir also"/>
  <result pre="workflow with hydroxychloroquine is provided in Fig.Â 3. Lopinavir and" exact="ritonavir" post="also have the potential to cause QTc prolongation [93]."/>
  <result pre="ritonavir also have the potential to cause QTc prolongation [93]." exact="Ribavirin" post="has the potential to cause hemolytic anemia in high"/>
  <result pre="CV adverse effects of experimental therapies. Fig. 3 Workflow for" exact="hydroxychloroquine" post="therapy in COVID-19 patients Table 3 Treatment modalities used"/>
  <result pre="adverse effects Therapy Rationale in CoVID-19 patients Cardiovascular adverse effects" exact="Chloroquine" post="and hydroxychloroquine 1. Inhibits the viral entry through endosomal"/>
  <result pre="Therapy Rationale in CoVID-19 patients Cardiovascular adverse effects Chloroquine and" exact="hydroxychloroquine" post="1. Inhibits the viral entry through endosomal trafficking 2."/>
  <result pre="ventricular arrhythmias, Torsades de pointe Lopinavir/ritonavir Lopinavir inhibits viral protease" exact="Ritonavir" post="inhibits CYP3A metabolism, increasing the half-life of lopinavir Conduction"/>
  <result pre="viral protease Ritonavir inhibits CYP3A metabolism, increasing the half-life of" exact="lopinavir" post="Conduction abnormalities Remdesivir Viral RNA polymerase inhibitor No serious"/>
  <result pre="Remdesivir Viral RNA polymerase inhibitor No serious cardiac adverse effects" exact="Ribavirin" post="Inhibits viral RNA and DNA replication Hemolytic anemia Corticosteroids"/>
  <result pre="18 May 2020. 66.US FDA. FDA cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
  <result pre="2020. 66.US FDA. FDA cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
  <result pre="haemophilia therapies in COVID-19J Thromb Haemost.202010.1111/jth.1484132558075 80.AsakuraHOgawaHPotential of heparin and" exact="nafamostat" post="combination therapy for COVID-19J Thromb Haemost.202010.1111/jth.1485832302456 81.LlitjosJFLeclercMChochoisCMonsallierJMRamakersMAuvrayMet al.High incidence"/>
  <result pre="treatments for coronavirus disease 2019 (COVID-19): a reviewJAMA20203231818241836 93.US FDA." exact="Kaletra" post="prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021251s046_021906s039lbl.pdf. Accessed 18 May 2020. 94.Al-TawfiqJAAl-HomoudAHMemishZARemdesivir as"/>
 </snippets>
</snippetsTree>
